Results 61 to 70 of about 704,437 (356)

Trends in clinical features and survival of oral cavity cancer: fifty years of experience with 3,362 consecutive cases from a single institution

Cancer Management and Research, 2018
Shu-Wei Chen,1–3,* Quan Zhang,1–3,* Zhu-Ming Guo,1–3 Wen-Kuan Chen,1–3 Wei-Wei Liu,1–3 Yan-Feng Chen,1–3 Qiu-Li Li,1–3 Xue-Kui Liu,1–3 Hao Li,1–3 Dian Ou-Yang,1–3 Wei-Chao Chen,1–3 Xiao ...
Chen SW, Zhang Q, Guo ZM, Chen WK, Liu WW, Chen YF, Li QL, Liu XK, Li H, Ou-Yang D, Chen WC, Fu XY, Wang XD, Yang AK, Bei JX, Song M   +15 more
doaj  

The changing landscape of vestibular schwannoma diagnosis and management: A cross-sectional study. [PDF]

, 2020
ObjectivesTo assess the current state of the diagnosis and management of vestibular schwannoma (VS) as well as treatment trends, and to evaluate the role of treatment setting and various specialists in treatment plan.MethodsPatients diagnosed with VS ...
Abouzari, Mehdi, Djalilian, Hamid R, Goshtasbi, Khodayar, Lin, Harrison W, Moshtaghi, Omid, Sahyouni, Ronald, Sajjadi, Autefeh   +6 more
core   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Decrypting cancer's spatial code: from single cells to tissue niches

Molecular Oncology, EarlyView.
Spatial transcriptomics maps gene activity across tissues, offering powerful insights into how cancer cells are organised, switch states and interact with their surroundings. This review outlines emerging computational, artificial intelligence (AI) and geospatial approaches to define cell states, uncover tumour niches and integrate spatial data with ...
Cenk Celik, Shi Pan, Eloise Withnell, Hou Wang Lam, Maria Secrier   +4 more
wiley   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Stage T4B head and neck cancer survival outcome comparisons based on treatment modality: is surgery a viable treatment option? [PDF]

, 2016
IMPORTANCE: Advanced stage head and neck cancers are often deemed unresectable due to the aggressive nature of the cancer. In evaluating survival patterns of patients with stage IVb tumors, it is valuable to determine whether patients who undergo ...
Kidwai, Neiha
core   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis [PDF]

, 2018
Background. There is little information about quality of life (QoL) for patients with end-stage kidney disease (ESKD) choosing conservative kidney management (CKM).
Barendse, Brown, Chandna, Da Silva-Gane, Davies, De Biase, Devins, Helvik, Hussain, Iyasere, Jakobsson, Jassal, Johansen, Kamar, Mahoney, Morton, Murphy, Murtagh, O'Connor, Okamoto, Rockwood, Roshanravan, Seow, Sexton, Shum, Verberne, Zigmond   +26 more
core   +4 more sources

Warts treatment modalities

Baghdad Medical Journal Of Students, 2020
Warts are common problem in the communities and caused by many types of human papilloma virus. There are many modalities of treatment in which none was shown to be perfect and only few were based on high-level clinical trials. Treatment should be individualized in practice depending on many factors like immunity status, age, number and sites of the ...
openaire   +2 more sources

A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications

Molecular Oncology, EarlyView.
Hypoxia reshapes tumour redox landscapes by altering compartmental ROS production (mitochondria, NOX, ER, peroxisomes). Accurate interpretation requires oxygen‐contextualised measurement (live biosensors, chemical probes, EPR, LC–MS) and awareness of artefacts (reoxygenation, probe specificity).
Lina Hacker, Elysia Sarsam, Stuart J. Conway, Ester M. Hammond   +3 more
wiley   +1 more source